Adjusted CHAT-AD for Alzheimer Disease

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Alzheimer Disease+1 More
Care Partner Hospital Assessment Tool - Behavioral
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

The purpose of this study is to see whether an adapted questionnaire called the Care Partner Hospital Assessment Tool (CHAT) for care partners of hospitalized patients living with Alzheimer's disease and related dementias (ADRD) (CHAT-AD) can help people with dementia receive better care after they go home from the hospital. Participants will be a care partner ('family member or friend') who provides unpaid care to a hospitalized adult relative or partner to help them take care of themselves because of dementia. Participants can expect to be in this study for 14 days.

Eligible Conditions
  • Alzheimer Disease
  • Dementia

Treatment Effectiveness

Study Objectives

2 Primary · 6 Secondary · Reporting Duration: 72 hours post-discharge

72 hours post-discharge
Care partner satisfaction of care
Feasibility measure: Implementation satisfaction
Post-treatment Qualitative Interviews: Attrition
Qualitative Feasibility measure: Adherence
Baseline
Feasibility measure: Time to complete assessments and CHAT-AD
Hour 72
Change in Preparedness for Caregiving
Change in care partner burden
Change in care partner depression

Trial Safety

Trial Design

2 Treatment Groups

Standard of Care
1 of 2
Adjusted CHAT-AD
1 of 2

Active Control

Experimental Treatment

128 Total Participants · 2 Treatment Groups

Primary Treatment: Adjusted CHAT-AD · No Placebo Group · N/A

Adjusted CHAT-AD
Behavioral
Experimental Group · 1 Intervention: Care Partner Hospital Assessment Tool · Intervention Types: Behavioral
Standard of CareNoIntervention Group · 1 Intervention: Standard of Care · Intervention Types:

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 72 hours post-discharge

Who is running the clinical trial?

University of Wisconsin, MadisonLead Sponsor
1,061 Previous Clinical Trials
2,563,681 Total Patients Enrolled
18 Trials studying Alzheimer Disease
11,534 Patients Enrolled for Alzheimer Disease
National Institutes of Health (NIH)NIH
2,418 Previous Clinical Trials
24,557,439 Total Patients Enrolled
27 Trials studying Alzheimer Disease
11,238 Patients Enrolled for Alzheimer Disease
Beth Fields, PhDPrincipal InvestigatorUniversity of Wisconsin, Madison

Eligibility Criteria

Age 18+ · All Participants · 2 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You must be at least 18 years old.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 26th, 2021

Last Reviewed: November 8th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.